Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

4D Pharma Plc (DDDD.LN)

4D Pharma Plc (DDDD.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
4D pharma plc (“4D pharma”) Receives Notice of Delisting From Nasdaq Business Wire - Tue Jun 28, 2022

4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces that...

DDDD.LN : 16.660 (unch)
LBPS : 1.6500 (+2.48%)
Update on Suspension of Trading Business Wire - Fri Jun 24, 2022

4D pharma plc (AIM: DDDD, Nasdaq: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, provides an update to...

LBPS : 1.6500 (+2.48%)
DDDD.LN : 16.660 (unch)
4D pharma Presents Trial in Progress Poster on Study of MRx0518 in Combination with BAVENCIO® in Patients with Unresectable Locally Advanced or Metastatic Urothelial Carcinoma at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Business Wire - Thu May 26, 2022

4D pharma plc (AIM: DDDD, NASDAQ: LBPS) , a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announced the...

DDDD.LN : 16.660 (unch)
LBPS : 1.6500 (+2.48%)
4D pharma to Present at the H.C. Wainwright Global Investment Conference Business Wire - Thu May 19, 2022

4D pharma plc (AIM: DDDD, NASDAQ: LBPS) , a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announced that...

LBPS : 1.6500 (+2.48%)
DDDD.LN : 16.660 (unch)
4D pharma Presents Late Breaking Abstract from Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma at the American Thoracic Society (ATS) 2022 International Conference Business Wire - Tue May 17, 2022

4D pharma plc (AIM: DDDD, NASDAQ: LBPS) , a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces the...

LBPS : 1.6500 (+2.48%)
DDDD.LN : 16.660 (unch)
4D pharma Reports Full Year 2021 Financial Results, Operational Highlights, and Guidance for Key Milestones in 2022 Business Wire - Thu Mar 31, 2022

4D pharma plc (AIM: DDDD, NASDAQ: LBPS) , a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today reported financial...

LBPS : 1.6500 (+2.48%)
DDDD.LN : 16.660 (unch)
4D pharma Announces Positive Interim Results from the Phase I/II Study of the Combination of MRx0518 and KEYTRUDA® (pembrolizumab) for the Treatment of Renal Cell Carcinoma Business Wire - Wed Mar 23, 2022

4D pharma plc (AIM: DDDD, NASDAQ: LBPS) , a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces that...

LBPS : 1.6500 (+2.48%)
DDDD.LN : 16.660 (unch)
4D pharma to Participate at the Chardan Metagenomics and Microbiome Medicines Summit Business Wire - Wed Feb 23, 2022

4D pharma plc (AIM: DDDD, NASDAQ: LBPS) , a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announced that...

LBPS : 1.6500 (+2.48%)
DDDD.LN : 16.660 (unch)
4D pharma Announces FDA Clearance of IND Application for Live Biotherapeutics MRx0005 and MRx0029 for the Treatment of Parkinson’s Disease Business Wire - Tue Feb 22, 2022

4D pharma plc (AIM: DDDD, NASDAQ: LBPS) , a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces...

LBPS : 1.6500 (+2.48%)
DDDD.LN : 16.660 (unch)
4D pharma Announces Additional Positive Data From Part A of the Phase I/II Trial Of MRx-4DP0004 For the Treatment of Asthma Business Wire - Thu Jan 27, 2022

4D pharma plc (AIM: DDDD, NASDAQ: LBPS) , a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces additional...

LBPS : 1.6500 (+2.48%)
DDDD.LN : 16.660 (unch)

Barchart Exclusives

3 High-Yield Dividend Stocks Ready to Soar Barchart - Fri May 3, 6:00PM CDT
These three stocks are cheap, pay a high dividend, and are highly rated. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot